Le 26 janvier à 17h50

(Unaudited data)

  • CUMULATIVE ACTIVITY AS OF THE END OF DECEMBER 2016
thousands of euros 2015 2016 Variation at current exchange rates Variation at constant exchange rates
France 361,765 370,870 +2.5% +2.5%
Europe (excluding France) 167,714 163,849 -2.3% -0.3%
North America 63,858 64,916 +1.7% +1.9%
Other countries 14,466 14,854 +2.7% +3.7%
Group total 607,803 614,489 +1.1% +1.7%

thousands of euros 2015 2016 Variation at current exchange rates Variation at constant exchange rates
Non-proprietary Homeopathic Medicines 310,555 313,365 +0.9% +0.9%
OTC Specialties 296,954 299,672 +0.9% +2.1%
Other 294 1,452 +393.9% +393.9%
Group total 607,803 614,489 +1.1% +1.7%
  • QUARTERLY ACTIVITY IN 2016 (variation at current exchange rate)
thousands of euros 1st quarter 2nd quarter 3rd quarter 4th quarter
2015 2016 Var.
16/15
2015 2016 Var. 16/15 2015 2016 Var.
16/15
2015 2016 Var.
16/15
France 89,584 90,494 +1.0% 76,864 80,469 +4.7% 97,767 98,840 +1.1% 97,550 101,067 +3.6%
Europe (excluding France) 40,657 43,685 +7.4% 29,943 31,572 +5.4% 50,614 41,273 -18.5% 46,500 47,319 +1.8%
North America 17,193 16,064 -6.6% 12,894 14,113 +9.5% 16,055 16,020 -0.2% 17,716 18,719 +5.7%
Other countries 4,622 3,846 -16.8% 3,816 4,061 +6.4% 3,594 3,280 -8.7% 2,434 3,667 +50.7%
Group total 152,056 154,089 +1.3% 123,517 130,215 +5.4% 168,030 159,413 -5.1% 164,200 170,772 +4.0%

thousands of euros 1st quarter 2nd quarter 3rd quarter 4th quarter
2015 2016 Var.
16/15
2015 2016 Var.
16/15
2015 2016 Var.
16/15
2015 2016 Var.
16/15
Non-proprietary Homeopathic Medicines 79,191 80,147 +1.2% 74,354 76,001 +2.2% 73,677 73,913 +0.3% 83,333 83,304 -0.0%
OTC Specialties 72,880 73,743 +1.2% 49,030 53,719 +9.6% 94,328 85,319 -9.6% 80,716 86,891 +7.7%
Other -15 199 - 133 495 +272.2% 25 181 +624.0% 151 577 +282.1%
Group total 152,056 154,089 +1.3% 123,517 130,215 +5.4% 168,030 159,413 -5.1% 164,200 170,772 +4.0%

HIGHLIGHTS OF THE FOURTH QUARTER

Sales revenue in the fourth quarter 2016 grew by 4% (+3.7% at constant rate). This growth is linked to the context of flu pathology at the end of the year.

Annual sales revenue amounted €614,489 thousand, in increase by 1.1% against 2015 (+1.7% at constant rate). Thus, the 2016 operating income will be slightly higher than in 2015.

On December 14, 2016, a project of new organization of the establishments in France has been presented to the Central Works Committee. The consultation with the social partners will continue until March 2017.

Our next update: March 15, 2017, after the close of the stock market, publication of 2016 results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com



Regulated information
News releases under ongoing reporting obligations:
- Information on annual revenues
- News releases under ongoing reporting obligations
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-47163-cp-boiron-260117.pdf
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Cette information ne provient pas de Daily-bourse. Elle est communiquée à titre indicatif et ne doit pas être considérée comme des conseils ou des recommandations. Daily-bourse ne saurait en aucun cas être tenue pour responsable de l'utilisation faite de cette information par les clients et prospects, et des conséquences financières, fiscales ou autres résultant des décisions financières prises par ses clients, notamment sur la base de cette information. Daily-bourse s'efforce de choisir des sources d'information dignes de confiance, qui s'efforcent d'assurer l'exactitude et la mise à jour des informations. Mais ni Daily-bourse, ni les sources externes d'information, ne peuvent en garantir en aucune façon l'absence d'erreur, l'exhaustivité, la qualité, la disponibilité, ou l'opportunité. Ces informations peuvent être protégées par le droit d'auteur. Il peut y avoir des restrictions ou interdictions de modifier, publier, rediffuser ou reproduire ces informations. Elles ne peuvent être utilisées qu'à des fins personnelles, à l'exclusion de toute utilisation commerciale.